Currency in EUR
Last close As at 26/05/2023
▲ −0.01 (−1.69%)
France-based Nicox develops therapeutics for the treatment of ocular conditions. Lead candidate NCX-470 is in Phase III studies for the treatment of glaucoma and it is advancing NCX-4251 for dry eye disease. Nicox receives licence revenue for its FDA-approved drugs Vyzulta and Zerviate.
In addition to its established intraocular pressure lowering activity, Nicox is starting a Phase IIIb study in H123 to investigate whether NCX-470 can provide improvements to retinal perfusion, which may provide an additional protective mechanism for glaucoma treatment. Nicox had €21.4m gross cash at 31 March 2023 and has guided that it is financed into Q224, based on the development of NCX-470 alone.
Executive VP and Chief Business Officer
Forecast net debt (€m)
Forecast gearing ratio (%)
|52 week high/low||€2.1/€0.6|
Nicox develops drugs for eye diseases, with lead candidate NCX-470 targeting the topical ocular treatment of glaucoma. NCX-470 combines an NO-donating molecule with an analogue of established prostaglandin F2a drug, bimatoprost. NCX-470 0.1% showed non-inferiority compared to latanoprost 0.005% in the lowering of intraocular pressure in the Mont-Blanc Phase III study and the company is pursuing a second Phase III study (Denali). Nicox also has a Phase II stage drug candidate in NCX-4251 for dry eye disease, which it is seeking to out-license for further development. The company also receives ongoing license revenue for Vyzulta and Zerviate.
|Y/E Dec||Revenue (€m)||EBITDA (€m)||PBT (€m)||EPS (fd) (c)||P/E (x)||P/CF (x)|